REFERENCES

1. Evaluate pharma, World Preview to 2016, May 2010.

2. IMS Health Forecasts 2011 Pharma Market Growth, Dec 2010.
3. Pharma Prognosis, Citigroup Global Markets, Industry, Oct 2009
4. IMS Market Prognosis, Apr 2011.
5. The Global Use of Medicines: Outlook Through 2015, Report by
the IMS Institute for Healthcare Informatics, May 2011.
6. Zacks Equity, Pharmaceutical Industry Outlook - Mar 2011
7. World Preview 2016 Evaluate Pharma, Jun 2011

215
8. World Review, 2005, Pharma Strategy Group, 2005
9. IMS Health, National Sales Perspectives, Sep 2010.
10. Lofgren H, Reshaping Australian Drug Policy: The Dilemmas of
Generic Medicines Policy, Australia and New Zealand Health
policy 4. 1, 2007:11-14.
11. Kadonga S and Kanzler L, “Building Japan’s Generic-Drug
Market, “McKinsey Quarterly, Dec 2007.
12. Frank RG. The ongoing regulation of generic drugs. N Engl J
Med. 357, 2007:1993-6.
13. IMS Health, Global pharmaceutical sales by Region- 2007, 2008.
14. Savings. An economic analysis of Generic drug usage in the U.S.
Generic Pharmaceutical Association, 2011.
15. E. Weisberg, Taming pharmacy: Driving out waste one consumer
at a time, “Express scripts, Presentation, May 27, 2008.
16. IMS Health Canada, pharmaceutical Trends: Generic Dispensing
Trend by Province, Canada, 2007: 2008
17. H. Lofgren, Reshaping Australian Drug Policy: The Dilemmas of
Generic Medicines Policy, Australia and New Zealand Health
policy 4. 1, 2007:11-14
18. S. Kadonga and L Kanzler, Building Japan’s Generic-Drug
Market, McKinsey Quarterly, Dec 2007
19. European Generic Medicine Association. The Role of Generic
Medicines in Europe, Sep 2007.
20. J.S. Haas, K. A. Phillips, E.P. Gerstenberger et al., Potential
Savings from Substituting Generic Drugs for Brand-Name
Drugs: Medical Expenditure Panel Survey, 1997-2000, Annals of
Internal Medicine, 142:891-897.
21. K. Jaeger, Generic Medicines Are Key to Medical Reform,
Pharmacy Times, 2005.
22. P. Leigh. Strategies to increase generic drug utilization and
associated service. AARP Public Policy Institute. 2008, 1-20.
23. National Association of Chain drug Stores, “Industry Facts-at-a-
Glance, 2008.
24. A. Daemmrich, U.S. Healthcare Reform and the Pharmaceutical
Industry, Working Paper, 2011.
25. D. Long, U.S. Pharmaceutical Market Trends: A Picture of
Increasing Trends, IMS Health 2009.

26. US Trade Stats Express, International Trade Administration,

Govt. of USA.

Economic Analysis Generic Pharmaceuticals 1999-2008: $734

Billion in Health Care Savings. GPhA Commissioned Analysis by
IMS. May 2009.

216
27. 2006 Chain Pharmacy Industry Profile, The National Association
of Chain Drug Stores.

28. Express Scripts Study Shows Substantial Savings Opportunity

for Consumers, states, Health Care Purchasers with Generics,
says GPhA, Generic Pharmaceutical Association, Press release,
16, 2005.
29. Savings. An economic analysis of Generic drug usage in the U.S.
Generic Pharmaceutical Association (GPhA), Sep 2011.
30. D. Long. The US Pharmaceutical Market: Trends, Issues, &
Outlook, IMS Jan 2011.
31. W. Greene. The Emergence of India’s Pharmaceutical Industry
and Implications for the U.S. Generic Drug Market, 2007.
32. C Chatterjee, New Suppliers & New Markets: Essays on the
Global Pharmaceutical Industry, July 2009. Public Policy and
Management Dissertation thesis.
33. S. Chauhduri. 2005, The WTO and India. Pharmaceutical
Industry, Oxford University Press, New Delhi, India.
34. HN. Joshi. Analysis of the Indian Pharmaceutical Industry with
Emphasis on Opportunities in 2005, Pharmaceutical
Technology. 2003: 74-94.
35. A. Chadha, Product cycles, Innovation, and Exports: A study of
Indian Pharmaceuticals, World Development. 37, 2009: 1478-
1483.
36. R. Chittoor, S. Ray. Internationalisation paths of Indian
Pharmaceutical firms – A strategic group analysis, Journal of
International Management. 13, 2007: 338-355.
37. Pharmexcil, 7th Annual Report, 2010-2011.
38. B. Poduri B, U. Vasireddy, JD Kumar, S. Lanka. Dominance of
European Union in World Pharmaceutical Trade, Journal of
Pharmaceutical Science and Technology Vol. 3(4) 2011: 575-585.
39. Nagaraj Naidu's speech at India-China Pharma Conference in
Shanghai - Jun 2011
40. PricewaterhouseCoopers. Global Pharmaceutical Companies
Need To Take An Even Closer Look At India, 2010 News Release.
41. Ellen F.M.’t Hoen, LL.M., The Global Politics of Pharmaceutical
Monopoly Power, AMB 2009.
42. N. Nattrass. Government Leadership and ARV Provision in
Developing Countries. Centre for social science research AIDS
and society research unit. Working paper no. 14.
43. S. Kannan. Testing times for India's pharma industry, Asia
Times, 2005.
44. S. Guenni. Industrial and health related aspects of a global IPR
regime in developing countries: case studies from the South,
Working Paper, No 7, 2006.

217
45. S. Aaron. “73 Generic drugs concoct their next move,” CNN
Money, Feb. 9, 2007.
46. DP Dubey. Globalization and its impact on the Indian
Pharmaceutical Industry, 1999.
47. IHS Global Insight, Increasing Demand for Indian Drugs
Prompts Calls for Permanent U.S. FDA Presence in India, 2007.
48. K. Kate. India and China forge ahead while Europe plays catch-
up. Generics bulletin, 2011: 20-22.
49. JD Kumar, M. Vishwajeet, PV Appaji, S. Lanka, B. Poduri.
Presence of Indian pharmaceutical industries in US market: An
empirical analysis, Journal of Generic Medicines. 6(4), 2009:
333–344.
50. Department of Commerce, Ministry of Commerce and Industry,
Government of India. Report of the Task Force, ‘strategy for
Increasing Exports of Pharmaceutical Products, 2008.
51. T.Ramesh, D.Saravanan et al., Regulatory Perspective for
Entering Global Pharma Markets, Pharma Times. 43(9),
2011:15-20.
52. Rick Ng. Drugs From Discovery to Approval. John Wiley & Sons,
Hoboken, 2004, 211.
53. L. Shargel and I. Kanfer. Generic Drug Development, Informa
Healthcare 2004, 211–225.
54. Interview with Sue Capie. CEO. PharmaVantage. 2009.
55. J. Bumpas and E. Betsch. Exploratory Study on Active
Pharmaceutical Ingredient Manufacturing for Essential
Medicines, 2009.
56. H. Grabowski, I. Cockburn and G. Long. The Market For Follow-
On Biologics: How Will It Evolve? Health Affairs, 25, 2006: 1291-
1301. 505(b)(2) Application, S. Weinberg, GuideBook for Drug
Regulatory Submission, John Wiley & Sons, Inc., 2009, 191-
194.
57. DO. Beers. Generic and Innovator drugs: A Guide to FDA
approval Requirements. Aspen Publishers, Inc., 2004, App. 35-8.

58. R. Khullar, A. Goel, G. Aggarwal. Generic Drugs-A Ground

Discussion, Int. J. Drug Dev. & Res., 3, 2011: 178-184.
59. GJ. Mossinghoff, "Overview of the Hatch-Waxman Act and Its
Impact on the Drug Development Process," Food and Drug Law
Journal 54(2), 1999:187–194.
60. LS. Welage, et al. Understanding the issues Scientific Issues
Embedded in the Generic Drug Approval Process. J Am Pharm
Assoc. 41(6), 2001:856-867.
61. Food and Drug Administration. Requirements for Submission of
In Vivo Bioequivalence Data. Federal Register 2003a, 68:640

218
62. M. Michelle. Greater Access to Generic Drugs: New FDA
Initiatives to Improve Drug Reviews and Reduce Legal Loopholes.
FDA Consumer, 37, 2003.
63. WO. Foye, Thomas L. Lemke, et al., Foye's principles of
medicinal chemistry, Lippincott Williams & Wilkins. 335
64. Chow SC. Individual bioequivalence: A review of the FDA draft
guidance. Drug Information Journal, 33, 1999:435-444.
65. Harris Interactive Inc., Attitudes and Beliefs About the Use of
Over-the-Counter Medicines: A Dose of Reality, 2002: 1-26.
66. U.S. Patent and Trademark Office. “General Information
Concerning Patents: Nature of Patent and Patent Rights.”
Available online at http://www.uspto.gov/go/pac/doc/general/.
Accesssed on July 27, 2007.
67. H. Don and T. Foster. “The Orange Book: The Food and Drug
Administration’s Advice on Therapeutic Equivalence,” American
Pharmacy Journal, NS30 (7), 1990: 403-405.
68. GJ. Glover. The Influence of Market Exclusivity on Drug
Availability and Medical Innovations. AAPS Journal.
2007; 9(3): E312-E316.

69. JR. Sanjuan. U.S and E.U Protection of Pharmaceutical Test

Data, Consumer Project on Technology, 2006: 1-25.

70. ES. Weiswasser and SL. Cunningham, 180-day exclusivity is

hotly contested, The National Law Journal, April 2002: 1-2.
71. Generic Initiative for Value and Efficacy (GIVE) page. U.S. Food
and Drug Administration Web site. Available at:
http://www.fda.gov/oc/initiatives/advance/generics.html.
Accessed October 22, 2007.
72. Drug Price Competition and Patent Term Restoration Act of
1984, Pub. L. No. 98-417, 98 Stat.1585 (codified in scattered
sections of 21 U.S.C., 35 U.S.C., and 42 U.S.C.)
73. J. Nguyen. FDA’s New Generic Initiative for Value and Efficiency
(GIVE). Health Matters, 2(5), 2007: Pg.2.
74. Federal Trade Commission, Generic Drug Entry Prior to Patent
Expiration: An FTC Study, July 2002.
http://www.ftc.gov/os/2002/07/genericdrugstudy.pdf.
75. LE. Panattoni. The effect of Paragraph IV decisions and generic
entry before patent expiration on brand pharmaceutical firms, J
Health Econ.; 30(1), 2011:126-45.
76. AM. Sokal , BA Gerstenblith. The Hatch-Waxman Act:
encouraging innovation and generic drug competition, Curr Top
Med Chem. 10(18), 2010:1950-9.
77. RD Huntington. Paragraph IV Litigation in the United States,
Rothwell, Figg, Ernst & Manbeck, 2009.
78. ParagraphFour.com.
219
 http://www.paragraphfour.com/explained/why_challenge.html
(Accessed on 01.12.2011).
79. Federal Trade Commission, Generic Drug Entry Prior to Patent
Expiration: An FTC Study, July 2002.
80. J. Brown, Quick Uptake: Generic Competitors have Devoured
Prozac Sales Faster than Eli Lilly Marketers Had Anticipated,
Med Ad News, December 2001, 26.
81. S Koliopoulos, T Hung, A Pollack, S Grehan. Brand Erosion by
Generics. EP Publications, BE403P1 - BE403P3
82. T. Wani, Patient’s Access to Pills: Fight between Generic and
Brand-name Drugs Continues, Indian J. Intell. Prop. L.,
2009:102-115
83. 3rd Edition, Patent Awards, Pharmexcil, 2010-11.
84. SP. Brooks. Markov Chain Monte Carlo and Its Application.
Journal of the Royal Statistical Society, 47(1), 1998: 69-100.
85. I. Michael. Orlov, Multiple Linear Regression Analysis Using
Microsoft Excel, 1996.
86. IMS Health, National Sales Perspectives, December 2010. Report
by the IMS Institute for Healthcare Informatics.
http://www.imshealth.com/deployedfiles/imshealth/Global/Co
ntent/StaticFile/Top_Line_Data/2010_Top_Therapeutic_Classes
_by_Sales.pdf (last accessed on 25.12.2011).
87. Movers and Shakers, A Review of Pharma Matters Report, April -
June 2011. Thomson Reuters.
http://thomsonreuters.com/content/science/pdf/ls/pharma_m
atters/movers_shakers-cwp-en_issue16.pdf (Accessed on
01.12.2011)
88. JD Kumar, V Mohan, PV Appaji, L Srinivas, P Balaram. Presence
of Indian pharmaceutical industries in US market: An empirical
analysis, Journal of Generic Medicines. 6(4), 2009: 333–344.
89. M. Sawant. Opportunity for India in the World Generics Market,
Frost & Sullivan,
http://pharmalicensing.com/public/articles/view/1144147543_
44324e57b031f/opportunity-for-india-in-the-world-generics-
market (last accessed on 24.11.2010)
90. IHS Global Insight. World Review, 2005, Pharma Strategy
Group, 2005 ibid.
91. Generic Pharmaceuticals Association, Biogenerics, GPhA
Position. http://www.gphaonline.org/issues/biogenerics (last
accessed on 24.11.2010)
92. Strides Arcolab expands in biologics, buying 70% stake in
Bangalore’s Inbiopro, The PharmaLetter, 2010.
http://www.thepharmaletter.com/file/100553/strides-arcolab-
expands-in-biologics-buying-70-stake-in-bangalores-
inbiopro.html (last accessed on 17.12.2011)

220